Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 58Leukemia 44Lymphoma 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Lymphoma, Non-Hodgkin 22Hodgkin Disease 22Myelodysplastic Syndromes 20Multiple Myeloma 17Leukemia, Myeloid, Acute 15Myeloproliferative Disorders 13Recurrence 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, T-Cell, Peripheral 10Lymphoma, Follicular 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Congenital Abnormalities 8Anemia, Aplastic 8Waldenstrom Macroglobulinemia 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Sezary Syndrome 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Mycosis Fungoides 6Lymphoma, T-Cell, Cutaneous 6

Interventions

Epoetin Alfa 10fludarabine phosphate 3Darbepoetin alfa 3Cyclophosphamide 3fludarabine 2ferric carboxymaltose 2Thiotepa 2Therapeutics 2Filgrastim 2Ferric Oxide, Saccharated 2Cyclosporine 2Busulfan 2Antilymphocyte Serum 2AP 1903 reagent 2venetoclax 1trametinib 1thymoglobulin 1siltuximab 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1obinutuzumab 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Alemtuzumab × Lymphoid × Clear all
NCT00801931 2019-03-27

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Columbia University

Phase 1/2 Terminated
1 enrolled 8 charts
CNSClassical hematologyLymphoidOther hematologic neoplasm

Anemia, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡